NASDAQ: PNTPoint Biopharma Global Inc Stock
$9.27+0.15 (+1.64%)
Updated Jun 2, 2023
PNT Price
$9.27
Fair Value Price
$9.40
Market Cap
$979.78M
52 Week Low
$5.59
52 Week High
$11.13
P/E
8.75x
P/B
2.08x
P/S
3.25x
PEG
N/A
Dividend Yield
N/A
Revenue
$236.04M
Earnings
$98.14M
Gross Margin
100%
Operating Margin
54.68%
Profit Margin
41.6%
Debt to Equity
0.18
Operating Cash Flow
$172M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PNT Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PNT ($9.27) is undervalued by 1.38% relative to our estimate of its Fair Value price of $9.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PNT ($9.27) is not significantly undervalued (1.38%) relative to our estimate of its Fair Value price of $9.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PNT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more PNT due diligence checks available for Premium users.
Be the first to know about important PNT news, forecast changes, insider trades & much more!
PNT News
Valuation
PNT fair value
Fair Value of PNT stock based on Discounted Cash Flow (DCF)
Price
$9.27
Fair Value
$9.40
Undervalued by
1.38%
PNT ($9.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PNT ($9.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.75x
Industry
11.51x
Market
52.69x
PNT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PNT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PNT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
5.2x
PNT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PNT's financial health
Profit margin
Revenue
$9.5M
Net Income
-$16.5M
Profit Margin
-174.8%
PNT's Earnings (EBIT) of $129.06M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$558.5M
Liabilities
$86.7M
Debt to equity
0.18
PNT's short-term assets ($434.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PNT's short-term assets ($434.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.4M
Investing
-$153.0M
Financing
$145.9k
PNT's operating cash flow ($171.62M)... subscribe to Premium to read more.
Debt Coverage Financials
PNT vs Biotech Stocks
Point Biopharma Global Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.